NOX (ASX) St Vincent’s Hospital LUPIN Study PR

Originally posted by Stayso 54: ↑

I note that Garth Brennan has recently been sacked as Head Coach of the NRL affiliated Gold Coast Titans. Success - or lack of it - attracts a lot of scrutiny in the world of professional sport. In short, they are situated on the bottom rung of the ladder and below where they were when he first assumed the top role less than two years ago.

The same set of expectations do not always seem to be applied to some CEO’s that run public companies. I think that many of us can think of one where over a period of maybe three years now, it’s CEO has overseen its share price tumble from around eight cents to just four.

How impressive!

On a head to head basis, there is simply no comparison between his performance and that of Noxopharm’s founding CEO. Using the sporting theme, his best is say eight cents and Professor Kelly’s is $1:80. It’s simply not apples for apples. That company is a shareholders nightmare where even the most astute investor would have to consider themselves extremely fortunate to come out in front. Anyone who bought upon his appointment to today would be well behind. Shareholders who still hold today what they purchased during the initial IPO remain over one hundred percent ahead. Top flight super funds in Australia are lucky to generate ten percent returns per annum. Again, it’s impossible to draw any logical or reasonable comparison on that basis.

And yet they love him over there. By the same set of standards, it’s not hard to see that Garth Brennan has been hard done by.

Now Harvet says that Noxopharm is falling behind on its timetables. And it has. Firstly, it’s always going to be an imprecise business trying to judge when things are going to take place. Much easier no doubt for drug development companies with either one or at most two drugs for one indication each.

The problem for Noxopharm, in my opinion, happens to be a good problem. I think they have only just come to realise just how good the science actually is and furthermore, what to do with it and where to progress. Among other things, LuPIN simply wasn’t on the radar at the initial stages, the science of STING is of course another.

Basically, I think Noxopharm is trying to wrangle with Big Pharma issues but only with small pharma resources, and that is why I believe it isn’t meeting some of the early expectations.

Using the sporting analogy that I started with, I think Noxopharm entered the bush league with a very good prospect but has now realised that we can not only mix it with the best, but he better than the best on the world stage. We have for instance. recently seen Professor Louise Emmett perform an oral presentation at SNMMI in the US.

World class candidates take time. Time management is a far less complicated for the beats with little chance of success.

Expand

Stayso
Excellent post
Yes Agree we see all too often biotechs promising the world and delivering next to zero - while remuneration is aplenty
imo
Amazing how many on HC ramp up these biotechs for years while price drifts near all time lows

Not to mention many have no money and histories of failure as a norm

At Nox they have developed their own pipeline drugs and now have a $26m facility in place
imo
Research all fundamentals , cash position and history
dyor

No.	Vol.	Price($)
1	17790	6.7¢

No.

Vol.

Price($)

17790

6.7¢

Price($)	Vol.	No.
7.0¢	4049	1

Price($)

Vol.

No.

7.0¢

4049

No.	Vol.	Price($)
1	17790	0.067
1	24715	0.066
1	15000	0.065
1	10000	0.064
1	100000	0.062

No.

Vol.

Price($)

17790

0.067

24715

0.066

15000

0.065

10000

0.064

100000

0.062

Price($)	Vol.	No.
0.070	4049	1
0.079	11999	1
0.080	12099	2
0.081	22345	2
0.090	52000	3

Price($)

Vol.

No.

0.070

4049

0.079

11999

0.080

12099

0.081

22345

0.090

52000

(20min delay)
Last 6.7¢		Change 0.001(1.52%)		Mkt cap ! $19.57M

Open	High	Low	Value	Volume
6.7¢	6.7¢	6.7¢	$818	12.21K

Stayso Excellent post Yes Agree we see all too often biotechs...

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Nimy to raise $1.21M to explore 'newsy' WA targets

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Bitcoin investors need to know the risks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Stayso Excellent post Yes Agree we see all too often biotechs...

Top Stories

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Nimy to raise $1.21M to explore 'newsy' WA targets

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Bitcoin investors need to know the risks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News